Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 8535
  • Home
  • Print this page
  • Email this page

   Table of Contents      
AUTHOR REPLY
Year : 2015  |  Volume : 63  |  Issue : 9  |  Page : 751-752

Author reply


Smt. Kanuri Santhamma Retina Vitreous Centre, L. V. Prasad Eye Institute, Hyderabad, Telangana, India

Date of Web Publication3-Dec-2015

Correspondence Address:
Dr. Jay Chhablani
Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Eye Institute, Kallam Anji Reddy Campus, L. V. Prasad Marg, Banjara Hills, Hyderabad - 500 034, Telangana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

How to cite this article:
Chhablani J. Author reply. Indian J Ophthalmol 2015;63:751-2

How to cite this URL:
Chhablani J. Author reply. Indian J Ophthalmol [serial online] 2015 [cited 2019 Oct 22];63:751-2. Available from: http://www.ijo.in/text.asp?2015/63/9/751/170983

Dear Sir,

I appreciate comments from the authors.[1] I am glad that article on ziv-aflibercept has attracted attention from readers for Indian Journal of Ophthalmology. I agree with the authors that we do not have long-term data on ziv-aflibercept; therefore, I reported short-term safety results. After observing no clinical side effects in injected eye on the 5th day, I injected in the other eye. The patient was stable during the treatment-free interval with visual acuity of 20/100 before the recurrent attack. The response to ziv-aflibercept was better than bevacizumab. Therefore, ziv-aflibercept was considered as the treatment of choice at 1-month follow-up as well. The patient is under regular treatment until now. Therefore, I am unable to comment upon whether ziv-aflibercept prolonged the treatment-free interval or not.

Again, I appreciate authors’ interest in this article.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Sen A, Mitra A, Malhotra PP, Gupta S. Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion. Indian J Ophthalmol 2015;63:752.  Back to cited text no. 1
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed537    
    Printed2    
    Emailed0    
    PDF Downloaded82    
    Comments [Add]    

Recommend this journal